Literature DB >> 2510931

Mesna excretion and ifosfamide nephrotoxicity in children.

M P Goren1, C B Pratt, W H Meyer, R K Wright, R K Dodge, M J Viar.   

Abstract

To characterize the excretion of 2-mercaptoethanesulfonate sodium (mesna) administered by intermittent infusion, urinary concentrations of mesna and its corresponding inactive disulfide were measured during 50 courses of ifosfamide (1.6 g/m2 for 5 days) and mesna (400 mg/m2 at 0.25, 4, and 6 h after each ifosfamide dose) administered i.v. to 19 patients. Some patients had previously received nephrotoxic therapy that might influence the excretion of mesna and its associated uroprotective effects. The median urinary free thiol concentration increased to 3 mM by 1 h after mesna infusion, declining to background levels by 4 h. The rate of mesna excretion correlated with the creatinine clearance rate in a subset of six patients. The proportion of mesna recovered in urine within 4 h after infusion was lower (P less than 0.05) in children who had evidence of preexisting renal tubular damage. Ifosfamide-induced tubular proteinuria was associated with lower urinary mesna recovery. Low urinary mesna concentrations indicated potentially subtherapeutic renal tubular levels. However, ifosfamide nephrotoxicity was subclinical and is not necessarily linked to differences in mesna excretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510931

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  The stability of mesna in beverages and syrup for oral administration.

Authors:  M P Goren; B A Lyman; J T Li
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Mesna or cysteine prevents chloroacetaldehyde-induced cell death of human proximal tubule cells.

Authors:  Gerald Schwerdt; Antje Kirchhoff; Ruth Freudinger; Brigitte Wollny; Andreas Benesic; Michael Gekle
Journal:  Pediatr Nephrol       Date:  2007-02-02       Impact factor: 3.714

3.  In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.

Authors:  Zeinab Yaseen; Christian Michoudet; Gabriel Baverel; Laurence Dubourg
Journal:  Pediatr Nephrol       Date:  2008-01-18       Impact factor: 3.714

Review 4.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells.

Authors:  M Mohrmann; S Ansorge; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.